One of the key claims of BPC-157 benefits is its use as an anti-inflammatory
Ethics declarations Ethics approval All experimental procedures were approved by the Institutional Animal Ethics Committee (IAEC) of Girijananda Chowdhury Institute of Pharmaceutical Science (Approval No: GIPS/IAEC/M.PH/PRO/25/2022), and the protocols were by CPCSEA guidelines
Technical Specifications Compound: Glycyl-L-Histidyl-L-Lysine Copper Complex (GHK-Cu) Format: Lyophilized peptide powder Strength: 50 mg per vial Purity: 9899% (COA included) Appearance: Blue-tinted lyophilized powder Category: Research peptide reagent Intended Use This product is intended solely for: Laboratory experimentation Controlled in-vitro research Molecular and biochemical pathway studies Metal-peptide interaction research Non-human preclinical modeling Academic and institutional scientific projects Not intended for: Human or animal consumption Injection, ingestion, inhalation, topical, or cosmetic use Medical, therapeutic, or dermatological applications This material is not approved by Health Canada, FDA, or any regulatory body for clinical or cosmetic use
Other cases of L-Carnitine deficiency have been found in cats with idiopathic hepatic lipidosis, commonly known as fatty liver disease
Lenmeldy is the first FDA-approved gene therapy for MLD, which is caused by a deficiency of the arylsulfatase A (ARSA) enzyme, a state that leads to a buildup of fatty substances in the cells
